SCHEMBL2185352

SCHEMBL2185352

CCOC(=O)c1nc(-c2cc(Br)c3ccccc3c2)ns1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 5/20 0.40
KMT2A Q03164 4/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 5/20 0.39
MAPT P10636 3/20 0.39
RAB9A P51151 3/20 0.39
TP53 P04637 2/20 0.39
HCRTR1 O43613 2/20 0.39
ALOX15 P16050 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CDC25B P30305 4/20 0.38
APAF1 O14727 1/20 0.38
CASP3 P42574 1/20 0.38
CASP6 P55212 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
MEN1 O00255 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16370488 0.80 ALDH1A1 (0.59) ALDH1A1L3MBTL1KDM4EKMT2AMAPK1
SCHEMBL2185252 0.80 ALOX5 (0.41) ALDH1A1L3MBTL1KDM4EKMT2AMAPK1
SCHEMBL4164682 0.79 FOS (0.46) ALDH1A1L3MBTL1MAPTRAB9ALMNA
SCHEMBL18614346 0.78 MAPT (0.54) ALDH1A1L3MBTL1KDM4EKMT2ASMN1; SMN2
SCHEMBL2184826 0.75 CDC7 (0.58) ALDH1A1KDM4ESMN1; SMN2MAPTRAB9A
SCHEMBL4114732 0.75 ALDH1A1 (0.51) ALDH1A1L3MBTL1KDM4EKMT2AMAPT
SCHEMBL4122529 0.74 PPARD (0.43) ALDH1A1L3MBTL1MAPTTP53ALOX15
SCHEMBL14527733 0.74 ALDH1A1 (0.45) ALDH1A1L3MBTL1KDM4EMAPK1MAPT
SCHEMBL1426050 0.73 MAPT (0.52) ALDH1A1L3MBTL1KDM4EKMT2ASMN1; SMN2
SCHEMBL4119854 0.72 ABL1 (0.47) KDM4EMAPTRAB9AALOX5GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2343279-B1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL (JP) 2018-02-28 EP disclosed
US-8263622-B2 Fused-ring derivative and medical application of same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-09-11 US disclosed
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-25 US disclosed
EP-2343279-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME XDH, OAT, PON1 ALDH1A1 185/4885L3MBTL1 1584/4885KDM4E 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.